Document
type: Class

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

Article
type: Class

English
type: Language

Information Content Entity
type: Class

16624090
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial

individual
rights: termsOfUse
date: 2026-08-04T02:17:13
publisher: First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial
type: Document
label: RDF description of First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial - http://irises.unimi.it/resource/item/363490

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial
type: Document
related by: 16624090
type: Academic Article
most specific type: Academic Article
type: Entity
language: English
type: Continuant
type: Thing
type: Article
type: Information Content Entity
type: Generically Dependent Continuant